Medpace
MEDP
729 hedge funds and large institutions have $11.5B invested in Medpace in 2026 Q1 according to their latest regulatory filings, with 86 funds opening new positions, 237 increasing their positions, 298 reducing their positions, and 132 closing their positions.
0.52% more ownership
Funds ownership: 84.39% → 84.9% (+0.52%)
7% less funds holding
Funds holding: 785 → 729 (-56)
14% less capital invested
Capital invested by funds: $13.4B → $11.5B (-$1.81B)
20% less repeat investments, than reductions
Existing positions increased: 237 | Existing positions reduced: 298
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
35% less first-time investments, than exits
New positions opened: 86 | Existing positions closed: 132
41% less call options, than puts
Call options by funds: $13.6M | Put options by funds: $23.2M
Top Buyers
Top Sellers
| 1 |
FPP
Findlay Park Partners
London,
United Kingdom
|
-$98M |
| 2 |
Goldman Sachs
New York
|
-$91.4M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$75.1M |
| 4 |
Morgan Stanley
New York
|
-$65.7M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$54.9M |
MEDP Hedge Fund Activity: Q1 2026 in Review
729 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Medpace (MEDP) for Q1 2026, worth a combined $11.5B — down 14% from $13.4B a quarter earlier.
Sellers outnumbered buyers: 132 funds closed out of MEDP and 86 opened new positions — a net loss of 46 holders — while 298 trimmed existing stakes and 237 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $88.5M. The largest seller was Findlay Park Partners, exiting entirely with an estimated $98M sold.
- 729 institutional investors held Medpace (MEDP) as of Q1 2026, down from 785 in Q4 2025.
- Funds reported $11.5B of Medpace stock for Q1 2026, down 14% quarter-over-quarter.
- 86 funds opened new Medpace positions in Q1 2026 and 132 closed out, a net change of -46 holders.
- The largest Medpace buyer in Q1 2026 was T. Rowe Price Associates, an estimated $88.5M added.
- The largest Medpace seller in Q1 2026 was Findlay Park Partners, an estimated $98M sold.
Based on aggregated 13F filings for Q1 2026.